Using multiple AT products may be the best option for dry eye

Article

A study demonstrated the efficacies of three different artificial tears (AT) and that a combination of these may offer the best solution to corneal surface diseases affecting eye lubrication

A study featured in the European Journal of Ophthalmology has demonstrated the efficacies of three different artificial tears (AT) and that a combination of these may offer the best solution to corneal surface diseases affecting eye lubrication.

Dr Gil Calvão-Santos et al., Ophthalmology Department, Centro Hospitalar de Entre o Duoro e Vouga-Unidade de Santa Maria da Feira, Portugal, split 27 patients with dry eye symptoms into 4 groups. Group A was administered Tears Again, B was given Optive, C received Opticol and D was the control group.

Patients were observed on day 0, 7 and 30 after being administered the AT. Data analysis was conducted, as well as tear break-up time (TBUT), Schirmer tests and Ocular Surface Disease Index.

The findings demonstrated no significant differences between any of the groups. From day 0 to 30 the amount of eyes with abnormal TBUT was reduced. However, eyes presenting with an average TBUT increased in all groups and Schirmer value decreased in groups B, C and D, but increased in group A.

Tear film was recovered in all of the AT groups, but AT targeting just the internal and intermediate layer caused a small decline on lachrymal production. It was suggested that different types of AT should be used on different layers of the eye for the treatment of corneal surface diseases affecting eye lubrication.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.